UbiPro™ Platform

Ubiquitin Proteasome System (UPS) regulates fundamental aspects of cell physiology. Dysfunction in UPS is responsible for many diseases, including cancer, cardiovascular, inflammatory and neurodegenerative diseases. Ubiquitin E3 ligases conjugate ubiquitin (Ub) to specific target proteins, signaling various consequences in cells such as degradation in the proteasome, protein trafficking. mitophagy and autophagy. Deubiquitylases (DUBs) remove Ub from target proteins. Ub conjugation and deconjugation both have physiological consequences, and both can be manipulated by small molecules for therapeutic effect.

Progenra has established an array of technologies that constitute the UbiPro™ Drug Discovery Platform. It is a comprehensive toolbox of HTS assays and technologies to study DUBs and E3 Ligases and perform HTS of our diverse collection of >700,000 drug-like small molecules. Using the UbiPro™ platform we have discovered and developed a diverse set of Molecular Glues (MGs) as well as novel E3 ligands suitable for PROTACs.